843 related articles for article (PubMed ID: 24762071)
21. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
[TBL] [Abstract][Full Text] [Related]
22. Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
Gilmore W; Lund BT; Li P; Levy AM; Kelland EE; Akbari O; Groshen S; Cen SY; Pelletier D; Weiner LP; Javed A; Dunn JE; Traboulsee AL
J Neuroinflammation; 2020 Jun; 17(1):189. PubMed ID: 32539719
[TBL] [Abstract][Full Text] [Related]
23. Alemtuzumab: a review of its use in patients with relapsing multiple sclerosis.
Garnock-Jones KP
Drugs; 2014 Mar; 74(4):489-504. PubMed ID: 24604792
[TBL] [Abstract][Full Text] [Related]
24. Emerging injectable therapies for multiple sclerosis.
Oh J; Calabresi PA
Lancet Neurol; 2013 Nov; 12(11):1115-26. PubMed ID: 24090587
[TBL] [Abstract][Full Text] [Related]
25. Alemtuzumab therapy for multiple sclerosis.
Coles AJ
Neurotherapeutics; 2013 Jan; 10(1):29-33. PubMed ID: 23184314
[TBL] [Abstract][Full Text] [Related]
26. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.
; Coles AJ; Compston DA; Selmaj KW; Lake SL; Moran S; Margolin DH; Norris K; Tandon PK
N Engl J Med; 2008 Oct; 359(17):1786-801. PubMed ID: 18946064
[TBL] [Abstract][Full Text] [Related]
27. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
von Kutzleben S; Pryce G; Giovannoni G; Baker D
Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
[TBL] [Abstract][Full Text] [Related]
28. An update on new and emerging therapies for relapsing-remitting multiple sclerosis.
Weinstock-Guttman B
Am J Manag Care; 2013 Nov; 19(17 Suppl):s343-54. PubMed ID: 24494635
[TBL] [Abstract][Full Text] [Related]
29. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
30. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a.
Rudick RA; Fisher E; Lee JC; Duda JT; Simon J
Mult Scler; 2000 Dec; 6(6):365-72. PubMed ID: 11212130
[TBL] [Abstract][Full Text] [Related]
31. Drug safety evaluation of alemtuzumab for multiple sclerosis.
Willis M; Robertson NP
Expert Opin Drug Saf; 2014 Aug; 13(8):1115-24. PubMed ID: 24935240
[TBL] [Abstract][Full Text] [Related]
32. Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab.
Klotz L; Meuth SG; Wiendl H
Clin Immunol; 2012 Jan; 142(1):25-30. PubMed ID: 21550857
[TBL] [Abstract][Full Text] [Related]
33. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.
Jones JL; Anderson JM; Phuah CL; Fox EJ; Selmaj K; Margolin D; Lake SL; Palmer J; Thompson SJ; Wilkins A; Webber DJ; Compston DA; Coles AJ
Brain; 2010 Aug; 133(Pt 8):2232-47. PubMed ID: 20659956
[TBL] [Abstract][Full Text] [Related]
34. Alemtuzumab: the advantages and challenges of a novel therapy in MS.
Menge T; Stüve O; Kieseier BC; Hartung HP
Neurology; 2014 Jul; 83(1):87-97. PubMed ID: 24920854
[TBL] [Abstract][Full Text] [Related]
35. Natalizumab for relapsing-remitting multiple sclerosis.
Horga A; Tintoré M
Neurologia; 2011; 26(6):357-68. PubMed ID: 21193250
[TBL] [Abstract][Full Text] [Related]
36. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
37. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL; Bar-Or A; Comi G; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Montalban X; Rammohan KW; Selmaj K; Traboulsee A; Wolinsky JS; Arnold DL; Klingelschmitt G; Masterman D; Fontoura P; Belachew S; Chin P; Mairon N; Garren H; Kappos L;
N Engl J Med; 2017 Jan; 376(3):221-234. PubMed ID: 28002679
[TBL] [Abstract][Full Text] [Related]
38. A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis.
Fox EJ; Sullivan HC; Gazda SK; Mayer L; O'Donnell L; Melia K; Lake SL
Eur J Neurol; 2012 Feb; 19(2):307-11. PubMed ID: 21899662
[TBL] [Abstract][Full Text] [Related]
39. [ALEMTUZUMAB: BENEFITS AND CHALLENGES OF A NEW THERAPY IN MULTIPLE SCLEROSIS].
Illés Z; Sejbaek T; Csépány T
Ideggyogy Sz; 2015 May; 68(5-6):155-64. PubMed ID: 26182606
[TBL] [Abstract][Full Text] [Related]
40. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V
Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]